Duocarmycins

Duocarmycins are naturally derived, exceptionally potent DNA-alkylating antitumor agents that bind the narrower, deeper AT-rich DNA minor groove and undergo adenine-N3 alkylation through an activated cyclopropane^[1]. Mechanistically, duocarmycin A forms a stable adenine-N3 adduct in synthetic oligonucleotides, while related analogues preserve sequence-selective adenine alkylation at AT-rich sites^[2][3]. These DNA lesions are substrates for nucleotide excision repair, and cellular studies show transcription-coupled adduct elimination dependent on functional repair pathways^[3]. In tumor models, duocarmycin analogues and duocarmycin-based ADC payloads show potent cytotoxicity across human tumor cell lines and activity in xenograft models^[3][4][5]. Compared with related CC-1065/duocarmycin alkylation subunits, changes in stereochemistry, hydrophobicity, and DNA-binding architecture alter sequence selectivity, alkylation efficiency, and biological potency^[1][6][7]. For experimental applications, duocarmycin-based payloads support ADC design because they provide DNA-damaging cytotoxic mechanisms distinct from microtubule-targeted payloads^[4][5].